Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Acquisition
Lilly Completes Acquisition of POINT Biopharma
Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...
Brand Name : PNT2002
Molecule Type : Small molecule
Upfront Cash : $1,400.0 million
December 27, 2023
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Acquisition
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Acquisition
Details : Through the acquisition, Lilly expands its oncology capabilities into next-generation radioligand therapies by including PNT2002 (177Lu-PNT2002), a PSMA targeted radioligand therapy in development for patients with metastatic castration-resistant prostat...
Brand Name : PNT2002
Molecule Type : Small molecule
Upfront Cash : $1,400.0 million
October 03, 2023
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Eli Lilly
Deal Size : $1,400.0 million
Deal Type : Acquisition
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
Details : The expanded agreement broadens the supply of ITM’s n.c.a. 177Lu to POINT to enable its usage in the clinical and potential future commercial development of the 177Lu-based molecules in POINT’s development pipeline, including 177Lu-PNT2002 for prosta...
Brand Name : PNT2002
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 31, 2023
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Point Biopharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Lantheus Holding
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 24, 2023
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Lantheus Holding
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
POINT Biopharma Completes Randomization in PNT2002's Phase 3 SPLASH Trial
Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
January 12, 2023
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Lantheus Holdings
Deal Size : $2,115.0 million
Deal Type : Agreement
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
Details : PNT2002 (Lu-177-PSMA-I&T) is a PSMA-Targeted therapy for metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177.
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : $260.0 million
December 20, 2022
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Lantheus Holdings
Deal Size : $2,115.0 million
Deal Type : Agreement
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Lantheus Holding
Deal Size : $2,115.0 million
Deal Type : Collaboration
Details : Lu-177-PSMA-I&T (Lu-177-PNT2002) is a PSMA-Targeted therapy for mCRPC. PSMA is overexpressed in the vast majority of prostate cancers, but very limited to normal tissues. PNT2002 combines a PSMA-targeted ligand, PSMA-I&T, with the beta-emitting radioisot...
Brand Name : 177Lu-PSMA-I&T
Molecule Type : Large molecule
Upfront Cash : $260.0 million
November 14, 2022
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Lantheus Holding
Deal Size : $2,115.0 million
Deal Type : Collaboration
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : $13.9 million
Deal Type : Public Offering
POINT Biopharma Announces Closing of Public Offering of 13,900,000 Shares of Common Stock
Details : POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002 (Lu-177-PSMA-I&T), pre-commercialization activities, and for working capital and other general corporat...
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 16, 2022
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : $13.9 million
Deal Type : Public Offering
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Piper Sandler
Deal Size : $125.0 million
Deal Type : Public Offering
POINT Biopharma Prices Public Offering of Common Stock
Details : POINT intends to use the net proceeds from the proposed offering, to fund clinical and preclinical research and development programs including PNT2002, pre-commercialization activities, and for working capital and other general corporate purposes.
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Piper Sandler
Deal Size : $125.0 million
Deal Type : Public Offering
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Key findings for PNT2002 (Lu-177-PSMA-I&T), include a median rPFS time of 11.5 months, along with a well-tolerated safety profile with no treatment-related deaths and few treatment-related AEs of grade 3 or higher.
Brand Name : PNT2002
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 09, 2022
Lead Product(s) : 177Lu-PNT2002
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?